Fig. 3.

Enhanced anti-proliferative effects following combined PRMT5 and PARP inhibition in ovarian cancer cell lines. A, Average growth death index of ovarian cancer cell lines treated with a double titration of GSK3326595 and niraparib. Cell lines were treated with the combination for 10 days and cell growth was determined by CTG (n = 3 per cell line). B, Average excess over Bliss synergy scores calculated from growth inhibition of ovarian cancer cell lines treated with a double titration of GSK3326595 and niraparib. C, Average excess of HSA synergy scores of ovarian cancer cell lines treated with double titration of GSK3326595 and niraparib. For B and C, values ≥ 10 considered synergistic and values ≤-10 considered antagonism. (n = 3 per cell line)